Komori
Sumitomo Seika Chemicals Company,Limited. (4008) · RiskMaterialised

Additional Provision and Risk of Additional Losses Due to Overbilling for Products

First written in FY2026-H1. 1 of 3 entries say "Worsened", first in 2026-05-12. Latest entry: FY2026.

3entries
2years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2026-H1Worsened2026-05-12 – FY20262025: 120252026: 22026
Same theme, other companies
Additional loss and compensation risk associated with overbilling for productsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026MaterialisedAnnual report

    「An additional loss was recorded as an extraordinary loss for compensation for lost profits incurred by the business partner in connection with the overbilling for products by a consolidated subsidiary.」

    The overbilling matter progressed from the additional-provision stage to the stage of recording ¥3,208 million in compensation for lost profits as an additional extraordinary loss.
  2. 2026-05-12WorsenedEarnings

    「Regarding the overbilling of customers for products at a consolidated subsidiary, compensation of ¥3,208 million for lost profits incurred by business partners has been additionally recorded as an extraordinary loss.」

    Expenses related to overbilling increased from ¥1,355 million in the previous fiscal year to ¥3,208 million, and an additional amount was recorded.
  3. FY2026-H1First statedAnnual report

    「In light of the status of discussions with the business partner concerning overbilling for products that occurred during the fiscal year ending March 2025, an additional provision for overbilling-related costs was recorded as an extraordinary loss, among other factors, resulting in ¥3,275 million, down 1.6% year on year. The Company additionally recorded a ¥1,284 million provision for overbilling-related costs during the current interim consolidated accounting period, taking into account the status of discussions with the business partner concerning the overbilling. Depending on the outcome of future discussions, the matter may have a further impact on the Company's consolidated results. However, as the amount of this impact is difficult to reasonably estimate at present, it has been disclosed as a contingent liability.」

    Regarding the overbilling for products that occurred during the fiscal year ending March 2025, an additional ¥1,284 million provision was recorded based on the status of discussions, and recognized as an extraordinary loss. Any additional impact on results arising from the outcome of future discussions has been disclosed as a contingent liability because it is difficult to reasonably estimate at present.
Moved together

"Recognition of impairment losses due to deteriorating business conditions in China and Japan" moved the same way as this thread, in the same document, in 2 of its 3 moves.

2★1
  1. ★This thread
  2. 1Recognition of impairment losses due to deteriorating business conditions in China and Japan2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Sumitomo Seika Chemicals Company,Limited. yet. It last moved in the Earnings of 2026-05-12: "Worsened".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Additional Provision and Risk of Additional Losses Due to Overbilling for Products | Sumitomo Seika Chemicals Company,Limited. (4008) | Komori